Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) EBT Margin: 2009-2025

Historic EBT Margin for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -12.74%.

  • Myriad Genetics' EBT Margin fell 280.00% to -12.74% in Q3 2025 from the same period last year, while for Sep 2025 it was -51.53%, marking a year-over-year decrease of 3738.00%. This contributed to the annual value of -14.74% for FY2024, which is 2007.00% up from last year.
  • Latest data reveals that Myriad Genetics reported EBT Margin of -12.74% as of Q3 2025, which was up 91.79% from -155.14% recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' EBT Margin peaked at 23.79% during Q3 2021, and registered a low of -155.14% during Q2 2025.
  • Moreover, its 3-year median value for EBT Margin was -17.59% (2024), whereas its average is -34.76%.
  • Per our database at Business Quant, Myriad Genetics' EBT Margin soared by 6,076bps in 2021 and then crashed by 13,755bps in 2025.
  • Quarterly analysis of 5 years shows Myriad Genetics' EBT Margin stood at -27.05% in 2021, then crashed by 225bps to -29.30% in 2022, then skyrocketed by 1,287bps to -16.43% in 2023, then tumbled by 214bps to -18.57% in 2024, then tumbled by 280bps to -12.74% in 2025.
  • Its EBT Margin was -12.74% in Q3 2025, compared to -155.14% in Q2 2025 and -15.01% in Q1 2025.